BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

952 related articles for article (PubMed ID: 20470309)

  • 1. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
    Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
    Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients.
    Lim W; Chadban S; Campbell S; Dent H; Russ G; McDonald S
    Transpl Int; 2010 Dec; 23(12):1207-15. PubMed ID: 20536789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies.
    Wissing KM; Fomegné G; Broeders N; Ghisdal L; Hoang AD; Mikhalski D; Donckier V; Vereerstraeten P; Abramowicz D
    Transplantation; 2008 Feb; 85(3):411-6. PubMed ID: 18322434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
    Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
    Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction Therapy, Rejection, and Graft Outcomes in Pediatric and Adolescent Kidney Transplant Recipients.
    Mincham CM; Wong G; Teixeira-Pinto A; Kennedy S; Alexander S; Larkins N; Lim WH
    Transplantation; 2017 Sep; 101(9):2146-2151. PubMed ID: 28832451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
    Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
    Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
    Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression.
    Mikhalski D; Wissing KM; Ghisdal L; Broeders N; Touly M; Hoang AD; Loi P; Mboti F; Donckier V; Vereerstraeten P; Abramowicz D
    Transplantation; 2008 Apr; 85(7 Suppl):S3-9. PubMed ID: 18401260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney transplantation in the US: an analysis of the OPTN/UNOS registry.
    Freitas MC
    Clin Transpl; 2011; ():1-16. PubMed ID: 22755397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The UNOS Scientific Renal Transplant Registry--ten years of kidney transplants.
    Cecka JM
    Clin Transpl; 1997; ():1-14. PubMed ID: 9919387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreas transplant outcomes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR).
    Gruessner AC; Sutherland DE
    Clin Transpl; 2008; ():45-56. PubMed ID: 19708445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ; Rossi AF; Courtney M; Gelb BD
    J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.